GenSight Biologics Announces its 2021 Money Calendar

PARIS–(Enterprise WIRE)–Regulatory Information: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma organization…

PARIS–(Enterprise WIRE)–Regulatory Information:

GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma organization focused on building and commercializing progressive gene therapies for retinal neurodegenerative health conditions and central nervous process problems, nowadays introduced its economical calendar for 2021.

Info

Day*

2020 4Q Hard cash Situation

January 19, 2021

2020 Full-12 months Financial Update and Statements

March 10, 2021

2021 1Q Hard cash Posture

April 20, 2021

Yearly Typical Meeting

April 29, 2021

2021 To start with-Half Fiscal Update and Statements

July 29, 2021

2021 3Q Cash Position

Oct 19, 2021

2021 4Q Cash Position

January 18, 2022

* This money calendar is presented for facts only and might be matter to improvements. The Company’s updated money calendar is obtainable on its corporate web page.

About GenSight Biologics

GenSight Biologics S.A. is a clinical-stage biopharma company targeted on developing and commercializing modern gene therapies for retinal neurodegenerative ailments and central anxious technique problems. GenSight Biologics’ pipeline leverages two main engineering platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in sufferers suffering from blinding retinal diseases. Working with its gene treatment-based mostly method, GenSight Biologics’ solution candidates are intended to be administered in a one therapy to every eye by intravitreal injection to present sufferers a sustainable practical visual recovery. Made as a therapy for Leber Hereditary Optic Neuropathy (LHON), GenSight Biologics’ lead solution prospect, LUMEVOQ® (GS010 lenadogene nolparvovec), is at this time in the critique section of its registration process in Europe, and in Stage III to move forward to a BLA filing in the U.S.